Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Research & Development (2022 - 2025)

Historic Research & Development for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $65.8 million.

  • Praxis Precision Medicines' Research & Development rose 5710.47% to $65.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.9 million, marking a year-over-year increase of 11473.28%. This contributed to the annual value of $152.4 million for FY2024, which is 7565.98% up from last year.
  • Latest data reveals that Praxis Precision Medicines reported Research & Development of $65.8 million as of Q3 2025, which was up 5710.47% from $63.0 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Research & Development ranged from a high of $65.8 million in Q3 2025 and a low of $17.3 million during Q3 2023
  • For the 4-year period, Praxis Precision Medicines' Research & Development averaged around $38.9 million, with its median value being $30.4 million (2022).
  • As far as peak fluctuations go, Praxis Precision Medicines' Research & Development plummeted by 5156.12% in 2023, and later surged by 20611.27% in 2024.
  • Praxis Precision Medicines' Research & Development (Quarter) stood at $28.3 million in 2022, then crashed by 35.09% to $18.4 million in 2023, then soared by 206.11% to $56.3 million in 2024, then grew by 16.89% to $65.8 million in 2025.
  • Its Research & Development stands at $65.8 million for Q3 2025, versus $63.0 million for Q2 2025 and $60.8 million for Q1 2025.